Saratov JOURNAL of Medical and Scientific Research

Hixozide in therapy of tuberculosis of bronchi

Year: 2014, volume 10 Issue: №2 Pages: 293-300
Heading: Phthisiology Article type: Original article
Authors: Morozova T.l., Barinboym O.N., Doktorova N.P., Danilov A.N.
Organization: Saratov State Medical University

The purpose of the article is to evaluate the efficacy and tolerability of the combined inhaled anti-TB preparation Hixozide for improving the effectiveness of medical treatment of patients suffering from tuberculosis of bronchus. Material and Methods. Hixozide (made in Russia), the active substance Hydroxymethylchinoxylindioxydum 100mg + Isoniazidum 250 mg, was delivered via inhalations using a compressor nebulizer within 21 days in the course of the complex chemotherapy. Inclusion criteria: newly diagnosed patients and patients with relapsed tuberculosis with the presence of tuberculousendobronchitis, drug sensitivity saved to isoniazid. Exclusion criteria: the state of preventing the appointment of adequate treatment, HIV-infection (group 1, n=30). The comparison group was consisted of patients receiving standard treatment in combination with inhaled administration of Isoniazid (group 2, n=21). Rezults. The clinical study has figured out: after a course of inhalations of Hixozide the clinical cure of bronchial tuberculosis occurs after the period of 2 months of treatment (according to the results of endoscopy of bronchi); more patients — 69.2% versus 38.1% in the comparison group, p=0,039 showed a positive trend during the nonspecific endobronchitis — 85,7% vs. 52,9%, p=0,017; the treatment and bacteriological conversion were achieved: 143±27 days in the first group vs. 164±32 days in the control group, p=0,019. Adverse reactions to Hixozide demanding its abolition occurred in 13,3%, they were stopped and did not affect the health of patients in the future. Conclusion. Inhaled Hixozide in the complex treatment of patients with tuberculosis accelerates clinical cure of tuberculosis of the bronchi, healing the lesions in the lung tissue and abacillation.

1. Kiseleva YuYu, Vasilyeva IA, Kazennyi BYa, et al. The topical issues of the treatment in patients with tuberculosis under the present conditions and the factors influencing the efficiency of chemotherapy. Tuberculosis and lung diseases 2012; (9): 16-21.
2. Tuberculosis in the Russian Federation, 2010: analytical review of the statistical indicators used in the Russian Federation. Moscow, 2011; 280 p.
3. Smerdin SV, Bogorodstkaya ЕМ, Sterlikov SA, et al. Effectiveness of standard chemotherapy regimens in pulmonary tuberculosis with bacterial excretion. Tuberculosis and lung diseases 2012; (2): 24-32.
4. Kuziev АА, Parpieva NN, Irgashev АА. The defeat of the bronchi with limited and common forms of pulmonary tuberculosis. Tuberculosis and lung diseases 2011; (4): 220
5. HIKSOZID. Instructions for use. poisk_preparatov/hixozid__28752.htm [18Feb 2014]
6. Glushkov RG., Sokolova GB. Hixozide, a novel combined antituberculosis preparation. Antibiotics and chemotherapy 2008; 53 (5-6): 11-13
7. Barlamov OP, Peleneva IM, Reykhard VV. Results of application of Hiksozid in complex therapy of patients by widespread forms of tuberculosis of lungs. Ftiziatriya i pul'monologiya 2013; 1 (6). [18 Feb2014]
8. Tyul'kova ТЕ, Kornachev AS, Kozlov NV. Experience with the drug Hiksozid In: Proceedings of the Congress: XXII National Congress on Respiratory Diseases; edited by Acad.A. G. Chuchalin. Moskow: DizaynPress, 2012; p. 293
9. Order of the Ministry of Health of the Russian Federation 2003 Mch 21 № 109 «On improvement of ТВ control activities in the Russian Federation». index.htm [18Feb 2014]
10. Order of the Ministry of Health of the Russian Federation 2004 Feb 13 № 50 «On introduction of the records and reports of ТВ monitoring», prime/doc/6229299/ [cited 2014 Feb 18].

2014_02_293-300.pdf989.31 KB

No votes yet